Biofrontera shares surge 12.95% premarket after reporting record Q4 revenues driven by Ameluz sales and pricing adjustments.

Biofrontera Inc. (BFRI) rose 12.95% in premarket trading following the announcement of record preliminary Q4 2025 revenues of $17.0–$17.5 million, a 35–39% year-over-year increase driven by strong sales of its Ameluz® photodynamic therapy product and a December pricing adjustment. The company also highlighted a transformational transaction with Biofrontera AG that improved gross margins and strengthened its financial foundation. Full-year 2025 revenues are projected to grow 11–13% to $41.5–$42.0 million. The CEO emphasized sustained business execution, customer engagement, and strategic momentum heading into 2026, reinforcing investor confidence in the stock’s growth trajectory.